ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

difamilast

Also written as “OPA-15406”, “1% OPA-15406 Ointment” and “0.3% OPA-15406 Ointment”.

Its studies are mostly in Dermatitis, Atopic, led by 3 companies.

Drug pageDifamilast: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 7, 201916 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only132 open or runningphase 3since Apr 7, 2019Oct 3, 2012Dec 2026phase 3 · NCT07173478
Aurobindo Pharma20 open or runningphase 3since Oct 5, 2022Oct 5, 2022none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 2since Oct 21, 2016Oct 21, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aurobindo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named difamilastINNProposed as its International Nonproprietary Name in WHO's List 118 · before, OPA-15406
  2. Oct 5, 2022First study: phase 3 study in Dermatitis, AtopicFirst studyNCT05571943 · 542 enrolled · United States
  3. Nov 1, 2022Phase 3 study in Dermatitis, AtopicNCT05608343 · 153 enrolled · United States

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 2 Aurobindo Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05608343Dermatitis, Atopic · United States3CompletedOct 27, 2023153
NCT05571943Dermatitis, Atopic · United States3CompletedJul 31, 2024542

How it is read

Names in the registry

  • “OPA-15406”, 7 entries
  • “1% OPA-15406 Ointment”, 3 entries
  • “0.3% OPA-15406 Ointment”, 2 entries
  • “Difamilast”, 2 entries
  • “1% OPA-15406”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.